What is Sermorelin?
Sermorelin is the synthetic form of GHRH(1–29) — the first 29 amino acids of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary to release growth hormone. Native GHRH is a 44-amino-acid peptide, but its receptor-activating information is concentrated in the front of the sequence, and GHRH(1–29) is described in the literature as the shortest fragment that retains the full growth-hormone-releasing activity of the parent hormone. Sermorelin is that fragment, prepared synthetically and amidated at the C-terminus (GHRH(1–29)-NH2).
Because it acts one step upstream of growth hormone itself, Sermorelin belongs to a family researchers call GHRH analogs — compounds that engage the GHRH receptor to prompt the pituitary's own growth-hormone release. It shares that receptor target with the stabilized full-length analog Tesamorelin and with CJC-1295. Historically, Sermorelin was also developed into a prescription agent (marketed as Geref) used in growth-hormone-axis evaluation; the material Peptora supplies is a laboratory research compound only and is not a medicine.
The essentials at a glance
GHRH(1–29) fragment
The synthetic first 29 residues of GHRH — the shortest sequence characterized as retaining full GHRH activity.
GHRH-receptor mechanism
Studied for how it engages the GHRH receptor on pituitary somatotrophs to prompt endogenous growth-hormone release.
GH / IGF-1 axis
Associated in research with pulsatile growth-hormone secretion and downstream IGF-1 signaling.
99%+ verified purity
HPLC-verified and confirmed by LC-MS, with a batch-specific certificate of analysis — research use only.
Work with research-grade Sermorelin
GHRH(1–29), HPLC-verified to 99%+ purity, with a batch-specific certificate of analysis in every order — for laboratory research use only.
View SermorelinThe GHRH(1–29) fragment: structure and activity
Native GHRH is a 44-amino-acid peptide released by the hypothalamus, but decades of peptide-chemistry research established that its receptor-activating information sits almost entirely in the N-terminal portion. Systematic structure-activity work on human GHRH mapped how much of the sequence is actually required to switch on the receptor:
- GHRH(1–29) is the minimal active core — structure-activity studies characterized the first 29 residues as the shortest fragment that retains the full growth-hormone-releasing potency of native GHRH(1–44).
- C-terminal amidation (–NH2) — Sermorelin is amidated at the C-terminus, a feature associated in the literature with the fragment's receptor activity.
- A short-acting profile — unmodified GHRH(1–29) is characterized as rapidly cleared, which is why later GHRH analogs added stabilizing modifications; Sermorelin itself is the unmodified fragment.
This places Sermorelin at the foundation of the GHRH-analog family: it is the compact, unmodified GHRH(1–29) sequence from which longer-acting research analogs were subsequently derived. The stabilized full-length analog Tesamorelin and the modified GHRH(1–29) analog CJC-1295 both build on the same receptor-targeting core.
How Sermorelin works: the GHRH-receptor mechanism
The mechanism researchers study centers on one receptor and the signaling cascade it sets in motion:
- GHRH receptor (GHRHR) — Sermorelin engages the GHRH receptor on somatotroph cells in the anterior pituitary, the same receptor engaged by native GHRH.
- Endogenous growth-hormone (GH) release — receptor activation is associated in research with stimulation of the pituitary's own growth-hormone secretion, rather than supplying GH directly.
- Pulsatile signaling — GHRH-driven release is characterized in the literature as pulsatile, and studies have examined how continuous GHRH(1–29) signaling interacts with intermittent somatostatin to shape GH pulse generation.
- Downstream IGF-1 — released GH is characterized as driving hepatic production of insulin-like growth factor 1 (IGF-1), a common downstream marker in GH-axis studies.
A recurring theme in the literature is that GHRH analogs act upstream — prompting the pituitary's own release while the body's feedback loops (including somatostatin) remain in place — which is the property that draws research interest to Sermorelin as a mechanistic tool for studying the growth-hormone axis.
The GHRH-analog family: Sermorelin, Tesamorelin & CJC-1295
Sermorelin is best understood alongside the other peptides researchers reach for when studying growth-hormone signaling. Two mechanism classes dominate that landscape — GHRH analogs, which act on the GHRH receptor, and growth-hormone secretagogues (GHRPs), which act on a different receptor entirely:
| Compound | Class | Notes |
|---|---|---|
| Sermorelin | GHRH analog | The unmodified GHRH(1–29) fragment — the shortest sequence characterized as retaining full GHRH activity. |
| Tesamorelin | GHRH analog | Stabilized synthetic analog of full-length GHRH(1–44), with an added trans-3-hexenoyl group described as improving stability. |
| CJC-1295 | GHRH analog | Modified GHRH(1–29); some forms carry a Drug Affinity Complex (DAC) described as extending half-life. |
| Ipamorelin | GHRP / GH secretagogue | Acts on the ghrelin / GH-secretagogue receptor — a different receptor class, often studied alongside GHRH analogs. |
The key distinction is receptor class: GHRH analogs (Tesamorelin, Sermorelin, CJC-1295) act on the GHRH receptor, whereas GHRPs / secretagogues such as Ipamorelin act on the ghrelin / growth-hormone-secretagogue receptor (GHS-R) — a separate pathway. Because the two classes stimulate GH through complementary routes, they are frequently studied together, which is why Peptora offers both standalone Sermorelin and combined GHRH-analog + secretagogue tools such as the CJC-1295 + Ipamorelin and Tesamorelin + Ipamorelin blends, each with its own batch-specific certificate of analysis.
What the research explores
In physiological and historical clinical research, GHRH(1–29) / Sermorelin has appeared across a handful of connected areas:
- Growth-hormone axis — how GHRH-receptor activation influences endogenous GH secretion and pulsatility in research models and human physiology studies.
- IGF-1 signaling — the downstream insulin-like growth factor 1 response used as a marker of GH-axis activity.
- GH-axis evaluation — GHRH(1–29) has been investigated as a probe of pituitary growth-hormone secretory capacity, the context in which it was historically developed as the agent Geref.
- Aging & the GH axis — clinical research has examined long-term administration of a GHRH(1–29) analog on endocrine and metabolic markers in age-advanced adults.
Two points of context matter here. First, much of this literature describes historical clinical research conducted under prescription-drug development (Geref), not the research-grade material Peptora supplies. Second, these are descriptions of published findings — they are not efficacy claims, and nothing here describes or endorses use outside controlled research.
Purity, testing & certificates of analysis
In research, the reliability of a result depends on the identity and purity of the material behind it. Every batch of Sermorelin from Peptora is HPLC-verified to 99%+ purity, confirmed by LC-MS identity testing, and screened across a full quality-control panel before release. Each order ships with a lot-specific certificate of analysis (COA) so the material can be matched to its documentation.
Researchers often choose Peptora precisely because this documentation is standard rather than optional. To understand what each figure on a report means, see the guide on purity and certificates of analysis and the overview of testing standards.
Handling Sermorelin in the laboratory
Sermorelin is supplied as a lyophilized (freeze-dried) powder. Before research use it is reconstituted with bacteriostatic water, which is sold separately. Careful handling preserves peptide integrity and the validity of downstream work:
- 1Allow the sealed vial to reach room temperature before opening.
- 2Add bacteriostatic water slowly against the vial wall; swirl gently and do not shake.
- 3Let the powder dissolve fully before drawing.
- 4Store the reconstituted solution refrigerated and protected from light.
Full step-by-step protocols live in the reconstitution guide and the storage guide. Following them consistently is one of the simplest ways to keep research reproducible.
Scientific references
The literature below is provided for educational context, per PubMed, and describes physiological, structure-activity, and historical clinical research on GHRH(1–29) / Sermorelin — not the laboratory research product supplied by Peptora. It is a summary of published findings, not clinical guidance.
- 1Grossman A, Savage MO, Besser GM. Growth hormone releasing hormone. Clin Endocrinol Metab. 1986;15(3):607-627. doi:10.1016/s0300-595x(86)80012-3 (PMID: 2429796).
- 2Cervini LA, Donaldson CJ, Koerber SC, et al. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. J Med Chem. 1998;41(5):717-727. doi:10.1021/jm970618s (PMID: 9513600).
- 3Wilton P, Chardet Y, Danielson B, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr Suppl. 1993;388:10-15. doi:10.1111/j.1651-2227.1993.tb12827.x (PMID: 8329825).
- 4Achermann JC, Hindmarsh PC, Robinson IC, et al. The relative roles of continuous growth hormone-releasing hormone (GHRH(1-29)NH2) and intermittent somatostatin(1-14) in growth hormone (GH) pulse generation: studies in normal and post cranial irradiated individuals. Clin Endocrinol (Oxf). 1999;51(5):575-585. doi:10.1046/j.1365-2265.1999.00839.x (PMID: 10594518).
- 5Neyzi O, Yordam N, Ocal G, et al. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatr Suppl. 1993;388:16-21. doi:10.1111/j.1651-2227.1993.tb12828.x (PMID: 8329826).
- 6Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. doi:10.1210/jcem.82.5.3943 (PMID: 9141536).
- 7Ross RJ, Rodda C, Tsagarakis S, et al. Treatment of growth-hormone deficiency with growth-hormone-releasing hormone. Lancet. 1987;1(8523):5-8. doi:10.1016/s0140-6736(87)90699-4 (PMID: 2879138).
Explore research-grade Sermorelin
HPLC-verified to 99%+ purity, batch-specific COA, fast U.S. shipping — for laboratory research use only.
View SermorelinKey takeaways
- Sermorelin is the synthetic GHRH(1–29) fragment of growth-hormone-releasing hormone — the shortest sequence characterized in the literature as retaining the full GHRH activity of the native 44-amino-acid hormone.
- It is studied for its action on the GHRH receptor on pituitary somatotrophs, where receptor activation is associated with pulsatile endogenous growth-hormone release and downstream IGF-1 signaling.
- Sermorelin anchors the GHRH-analog family alongside tesamorelin (a stabilized full-length analog) and CJC-1295 (a modified GHRH(1–29)); GH secretagogues such as ipamorelin act on a different (ghrelin) receptor and are often studied together with it.
- GHRH(1–29) has a documented history in physiological and clinical research — including growth-hormone-axis evaluation — and was historically developed into the prescription agent Geref; the material Peptora supplies is a research compound only, not that drug.
- In the literature it appears across growth-hormone-axis, IGF-1, pulsatile-secretion, and aging GH-axis research models — for laboratory research use only.
- Peptora's Sermorelin is a lyophilized powder, HPLC-verified to 99%+ purity with a lot-specific certificate of analysis, reconstituted with bacteriostatic water before research use.
Frequently asked questions
This article is intended solely as an educational summary of publicly available scientific literature. Products offered by Peptora are supplied exclusively for laboratory research purposes and are not approved for human or veterinary use. The information presented should not be interpreted as medical advice, treatment recommendations, or clinical guidance.
